Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
When we turn our attention to emerging global threats, we know what to expect: grim statistics, dire predictions, and—perhaps worst of all—disturbing revelations that no preventive or corrective ...
A new T-cell therapy showed benefits in patients with relapsed/refractory multiple myeloma. Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results